Dow Jones Newswires: AstraZeneca says COVID-19 booster effective against omicron in study

Antibody levels against omicron following a third dose of its vaccine were broadly similar to antibody levels against the Delta variant achieved after two doses, said the pharmaceutical group.

Antibody levels against omicron following a third dose of its vaccine were broadly similar to antibody levels against the Delta variant achieved after two doses, said the pharmaceutical group.